Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesAsset Writedowns and ImpairmentCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Accured ExpensesChange in CashChange in IntangiblesChange in InventoryChange in ReceivablesDepreciation & Amortization (CF)Depreciation and DepletionExchange Rate EffectFree Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresNet Cash FlowNet IncomeNon-cash ItemsOther Working Capital ChangesOther financing activitiesSales of Property, Plant and EquipmentShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Cytosorbents (CTSO) Cash from Financing Activities (2016 - 2025)

Cytosorbents' Cash from Financing Activities history spans 15 years, with the latest figure at $2.5 million for Q4 2025.

  • Quarterly results put Cash from Financing Activities at $2.5 million for Q4 2025, up 1383.83% from a year ago — trailing twelve months through Dec 2025 was $9.3 million (changed 0.24% YoY), and the annual figure for FY2025 was $9.3 million, changed 0.24%.
  • Cash from Financing Activities for Q4 2025 was $2.5 million at Cytosorbents, up from -$1134.0 in the prior quarter.
  • In the past five years, Cash from Financing Activities ranged from a high of $12.2 million in Q4 2023 to a low of -$571762.0 in Q1 2024.
  • The 5-year median for Cash from Financing Activities is $589718.0 (2021), against an average of $2.3 million.
  • The sharpest move saw Cash from Financing Activities soared 6278.64% in 2022, then tumbled 183.56% in 2024.
  • Year by year, Cash from Financing Activities stood at -$80924.0 in 2021, then soared by 6278.64% to $5.0 million in 2022, then skyrocketed by 144.21% to $12.2 million in 2023, then tumbled by 98.63% to $167000.0 in 2024, then surged by 1383.83% to $2.5 million in 2025.
  • According to Business Quant data, Cash from Financing Activities over the past three periods came in at $2.5 million, -$1134.0, and $6.8 million for Q4 2025, Q2 2025, and Q1 2025 respectively.